https://www.selleckchem.com/pr....oducts/isoproterenol
Data on the safety of growth hormone (GH) replacement therapy during pregnancy are limited. We report a combined analysis of data from pregnant women treated with GH while enrolled in two non-interventional, multicenter studies NordiNet® International Outcome Study (IOS) and the American Norditropin® Studies Web-Enabled Research (ANSWER) Program. Pregnancy data were pooled from NordiNet®IOS and the ANSWER Program. Data were collected during routine clinic visits by participating physicians using a web-based syste
Like
Comment
Share
